Earnings Call · Q2 FY2022·2022-08-08

Q2 22EPS +16.00%·Rev n/aQ1 22EPS -16.67%·Rev n/aQ4 21EPS -12.50%·Rev n/aQ3 21EPS +65.38%·Rev n/a⚠ consensus missing

ACADIA PHARMACEUTICALS INC ACAD

Mark Johnson — Vice President

Stephen Davis — Chief Executive Officer

Mark Schneyer — Chief Financial Officer

Brendan Teehan — Head of Commercial Organization

Kathie Bishop — Head of Clinical Development or similar role in clinical/medical affairs

Srdjan Stankovic — Head of Research and Development or similar role

−2.4%1d on move date−2.0% vs SPY3d−5.3%5d−0.1%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ACAD calls or request research access.

More ACAD calls Browse calls Request research access